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A B S T R A C T
Past murine studies of phenylketonuria (PKU) have documented significant effects on cerebellum at both the
gross and cellular levels. The profile of neurocognitive and motor difficulties associated with early-treated PKU
(ETPKU) is also consistent with potential cerebellar involvement. Previous neuroanatomical studies of cere-
bellum in patients with PKU, however, have yielded mixed results. The objective of the present study was to
further examine potential differences in cerebellar morphometry between individuals with and without ETPKU.
To this end, we analyzed high resolution T1-weighted MR images from a sample of 20 individuals with ETPKU
and an age-matched comparison group of 20 healthy individuals without PKU. Measurements of whole brain
volume, whole cerebellum volume, cerebellar gray matter volume, and cerebellar white matter volume were
collected by means of semiautomatic volumetric analysis. Data analysis revealed no significant group differences
in whole brain volume, whole cerebellar volume, or cerebellar white matter volume. A significant reduction in
cerebellar gray matter volume, however, was observed for the ETPKU group compared to the non-PKU com-
parison group. These findings expand on previous animal work suggesting that cerebellar gray matter is im-
pacted by PKU. It is also consistent with the hypothesis that the cognitive difficulties experienced by individuals
with ETPKU may be related to disruptions in gray matter. Additional studies are needed to fully elucidate the
timing and extent of the impact of ETPKU on cerebellum and the associated neurocognitive consequences.
1. Introduction
Phenylketonuria (PKU) is an autosomal recessive disorder affecting
metabolism of the amino acid phenylalanine (Phe) into tyrosine, a
precursor for dopamine and other neurotransmitters. The net results of
altered Phe metabolism in PKU include decreased neurotransmitter
production, oxidative stress, and disruption in protein synthesis [1–3].
The severity of these results can be ameliorated by early and continuous
implementation of a Phe-restricted diet [4,5]. Although individuals
with early-treated PKU (ETPKU) are spared the more severe impair-
ments associated with untreated PKU [6], they do experience some
neurologic and cognitive sequelae. ETPKU is associated with impair-
ment of executive aspects of language, memory, learning, and attention
control [7–10]. Additional work has also shown individuals with
ETPKU to have deficits in fine motor control and information proces-
sing speed [11–15].
Recent work has shown that deficits in learning, attention, language
(including verbal working memory), as well as motor control and in-
formation processing are observed in individuals with damage to the
cerebellum [16,17]. Although the cerebellum has traditionally been
associated with motor skills and coordination via its projections to
primary motor cortex, it is now known that it also has similar reciprocal
connections with non-motor prefrontal cortex [18,19], a region that
plays a critical role in higher order cognitive abilities such as executive
function [20] and is known to be affected in ETPKU [21,22].
Little is known regarding the potential impact of ETPKU on the
cerebellum. Atypical findings such as reduced cell count and dendritic
arborization of cerebellar Purkinje cells are noted in a handful of early
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histological case studies of untreated PKU [23,24]. Findings for ETPKU
are less clear. Whereas one study found depressed glucose metabolism
in cerebellum in a sample of individuals with ETPKU [25], neuroima-
ging studies of gross anatomical morphology and structure have yielded
little evidence of ETPKU-related cerebellar abnormalities. For example,
a study by Hajek et al. [26] found lesions in cerebellar white matter in
only a small portion (20%) of a sample of 20 individuals with ETPKU
and Pietz et al. [27] found< 10% to have lesions in a sample of 51
subjects. In another study, Pearsen et al. reported no visual evidence of
involvement of cerebellar gray or white matter in a sample of 15 pa-
tients with ETPKU [28]. Lastly, Pfaender et al. found no significant
difference in overall cerebellar volume between individuals with and
without ETPKU [29].
1.1. The present study
The goal of the present study was to evaluate the effects of ETPKU
on the cerebellum by examining different aspects of cerebellar volume
within a single sample of individuals with ETPKU. We used structural
MRI to examine cerebellar volume, as well as volume of the gray matter
(GM) and white matter (WM) components of the cerebellum separately.
Given the particular cognitive and motor difficulties observed in in-
dividuals with ETPKU and their association with the cerebellum and its
connections (particularly with frontal cortex), we hypothesized that
cerebellar dysmorphology would be present in individuals with ETPKU.
2. Methods
2.1. Participants
Our study sample consisted of 20 participants (11 males, 9 females)
with ETPKU ranging in age from 11 to 27 years (M = 16.0, SD = 3.8).
Individuals with ETPKU were diagnosed shortly after birth and a Phe-
restricted dietary treatment was implemented at that time, as indicated
by medical records and/or patient report. Complete lifetime records of
blood Phe levels were available for 16 of the 20 of the participants in
the sample (M = 465.6 μmol/L, SD = 242). Recent blood Phe levels
were available for 19 of the 20 participants; the mean blood Phe level
over the year prior to testing was 620.5 μmol/L (SD = 369), and the
mean level over the three months prior to testing was 593.3 μmol/L
(SD = 356). None of the participants were being treated with sa-
propterin at the time of testing. Individuals with major medical
Fig. 1. Illustration of example volume segmentations using Analyze © software. A) 3D reconstruction of WBV; B) coronal view of segmentation of WBV; C,D) 3D
reconstructions of cerebellar WM and GM, respectively; E) coronal view of segmentation of cerebellar WM and GM.
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disorders unrelated to PKU or severe cognitive impairment were ex-
cluded.
A sample of 20 healthy individuals without PKU (10 males, 10 fe-
males) ranging in age from 11 to 27 years (M = 16.2, SD = 3.8)
comprised an age- and gender-matched control group. Healthy non-
PKU participants were recruited from the Columbia and St. Louis,
Missouri communities.
The Wechsler Abbreviated Scale of Intelligence [30] was adminis-
tered to estimate general intellectual ability. For individuals in the
ETPKU group, scores ranged from 76 to 124, with a mean of 106.3
(SD = 11.8). For individuals in the control group, scores ranged from
84 to 139, with a mean of 113.9 (SD = 13.4). The scores of the non-
PKU group were higher than those of the ETPKU group though not
statistically significantly different [t (38) = 1.90, p = 0.07].
2.2. MRI data acquisition
The present study was approved by the University of Missouri
Internal Review Board (Review ID 1091119) and was carried out in
accordance with the provisions of the World Medical Association
Declaration of Helsinki. Informed consent was obtained for all in-
dividuals prior to participation.
High-resolution T1-weighted MP-RAGE magnetic resonance ima-
ging (MRI) data were collected for all individuals with a 1.5 T scanner
(TR = 1920 ms, TE = 4 ms, flip angle = 8°, in-plane
resolution = 0.98 × 0.98 mm, slice thickness = 1 mm, number of
slices = 160), or a 3 T scanner (TR = 1900 ms, TE = 3.93 ms, flip
angle = 15°, in-plane resolution = 1 × 1 mm, slice thickness = 1 mm,
number of slices = 160).
2.3. Data processing & analysis
Measurements of whole brain volume (WBV), whole cerebellum
volume (WCV), cerebellar GM volume, and cerebellar WM volume were
collected by means of semiautomatic volumetric analysis. Analyze 10.0
© software [31] was used to obtain all volume measures, and all data
were processed by a single trained observer (KKC). WBV was defined as
the supratentorial cerebrum, infratentorial cerebellum and brainstem
(midbrain, pons and medulla) not including the meninges (Fig. 1 A,B).
A horizontal line was drawn across the plane of the foramen magnum to
represent the inferior boundary of the whole brain volume. WCV was
defined as the infratentorial cerebellum not including the brainstem
(midbrain, pons and medulla), tentorium cerebelli or CSF; cerebellar
GM volume was defined as the cortical tissue of the hemispheres and
the vermis; cerebellar WM was defined as the arbor vitae and the su-
perior, middle and inferior peduncles within the hemispheres (Fig. 1
C,D,E).
First, the semiautomatic analysis involves an automated seed-tool
that segments regions of interest (ROIs) values based on intensity, and
then a drawing tool is used to manually refine the borders of the ROIs
originally defined by the automated tool. Anatomical features of the
cerebellar peduncles were used as a guide to distinguish between cer-
ebellum and brainstem. A consistent line was manually drawn on each
of the images following the tissue boundary of 1) the midbrain to the
superior cerebellar peduncle, 2) the pons to the middle cerebellar
peduncle, and 3) the medulla to the inferior cerebellar peduncle; these
boundaries were defined following Woolsey et al. [32]. Tentorium
cerebelli and CSF were not included in any of the measures and were
manually deleted from all ROIs.
In order to establish intra-rater reliability, three of the 40 images
were randomly selected from the group of participants, blind to diag-
nosis. The cerebellum of each of the selected images was semi-auto-
matically segmented three times as described above. Intra-rater relia-
bility was assessed for each measure using a nested ANOVA in which
the volume served as the dependent variable, subject and trial-within-
subject were independent variables. No effect of trial was observed for
any structure (p= 0.21–0.60). These values show that segmentation of
the cerebellum was performed with a high degree of repeatability.
Table 1
Structural volumes in non-PKU and ETPKU individuals. Whole brain volume
(WBV), whole cerebellar volume (WCV), cerebellar gray matter volume (CGM),
and cerebellar white matter volume (CWM). Volumes measured in mm3.
Non-PKU n = 20 ETPKU n = 20 ETPKU/Non-
PKU
Volume % WBV Volume % WBV Mean
Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
% difference
WBV 1,112,057
(147939)
– 1,172,660
(129897)
– + 5.4%
WCV 121,680
(15532)
10.99
(0.98)
122,218
(17886)
10.41
(0.90)
- 5.6%
CGM 77,285
(10664)
6.98
(0.67)
75,820
(12977)
6.45
(0.76)
- 8.1%
CWM 44,395
(6031)
4.02
(0.45)
46,398
(6799)
3.96
(0.42)
- 1.4%
Fig. 2. Box and whisker plots of volume measures (mm3): WBV, WCV, cerebellar GM, and cerebellar WM in ETPKU and non-PKU groups. * Significant group
difference (p < 0.05).
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3. Results
Mean volumes for each structure are shown in Table 1 and Fig. 2.
3.1. Whole brain volume (WBV)
Hierarchical regression was employed to evaluate between-group
differences in whole brain volume. This method allows evaluation of
group-related differences in volume measures while accounting for the
effects of individual differences in age. Whole brain volume served as
the dependent variable. The first step of the analysis included age. The
second step included group (ETPKU and non-PKU), with the age x
group interaction included in the third (and final) step of the model.
There were no significant effects of age or group (ETPKU and non-PKU)
on whole brain volume (WBV) [t (37)< 1.4, pr2 < 0.05, p > 0.18 in
both instances]. The interaction between age and group was also not
significant [t (36) = 1.20, pr2 = 0.04, p = 0.24].
3.2. Cerebellar volumes
Hierarchical regression was employed to evaluate between-group
differences in cerebellar volume measures, allowing evaluation of
group-related differences in volume measures while controlling for the
effects of individual differences in age and whole brain volume. In each
hierarchical regression analysis conducted, the volume of the cerebellar
structure (WCV, GM, WM) served as the dependent variable. In the first
step of each analysis, age and WBV were included. The second step
included group (ETPKU and non-PKU). The third step included all
pairwise interactions (age x group, age x WBV, group x WBV), with the
age x group x WBV interaction included in the final step of the model.
3.3. Whole cerebellar volume (WCV)
The effect of WBV on WCV was significant [t (37) = 7.45,
pr2 = 0.60, p < 0.001] while age was not [t (37) = 1.58, pr2 = 0.06,
p = 0.12]. After accounting for age and WBV, no effect of group was
observed [t (36) = 1.57, pr2 = 0.06, p = 0.13]. However, the age x
group interaction approached significance [t (33) = 1.78, pr2 = 0.09,
p = 0.085] with WCV decreasing with age in the ETPKU group, while
remaining stable in the non-PKU group. There were no significant ef-
fects of age x WBV [t (33)< 1, pr2 = 0.004, p= 0.71], group x WBV [t
(33) = 1.63, pr2= 0.075, p= 0.11], or age x group x WBV [t (32)< 1,
pr2 = 0.002, p = 0.82].
3.4. Cerebellar White matter (WM) volume
WBV contributed significantly to cerebellar WM volume [t (37) =
5.73, pr2 = 0.47, p < 0.001], and the effect of age approached sig-
nificance [t (37) = 1.92, pr2 = 0.09, p = 0.063]. After accounting for
variance related to WBV and age, there was no effect of group [t
(36)< 1, pr2 < 0.001, p= 0.95]. The effect of age x group interaction
approached significance [t (35) = 1.74, pr2 = 0.08, p = 0.091]. A
significant decrease in WM volume was apparent when comparing
younger (< 16 yrs) and older (> 16 yrs) participants with ETPKU
(M = 10.9% and 10.0% of WBV, respectively) [t (18) = 2.60,
p = 0.018]. In contrast, WM volume was comparable for younger and
older participants in the non-PKU group (M = 10.8% and 11.2% of
WBV, respectively) [t (18)< 1, p = 0.38]. There were no significant
effects of age x WBV [t (33)< 1, pr2 < 0.001, p= 0.92], group x WBV
[t (33) = 1.25, pr2 = 0.05, p = 0.22], or age x group x WBV [t
(32)< 1, pr2 = 0.006, p = 0.65].
3.5. Cerebellar Gray matter (GM) volume
The effect of WBV on cerebellar GM volume was significant [t (37)
= 6.19, pr2 = 0.51, p < 0.001], while age was not [t (37)< 1,
pr2 = 0.02, p= 0.36]. After accounting for age and WBV, a significant
effect of group was observed [t (36) = 2.06, pr2 = 0.11, p = 0.047],
with GM reduced in the ETPKU group (M = 6.45% of WBV) as com-
pared to the non-PKU group (M = 6.98% of WBV). There were no
significant effects of age x group [t (33) = 1.18, pr2 = 0.04, p= 0.25],
age x WBV [t (33)< 1, pr2 = 0.008, p= 0.60], group x WBV [t (33) =
1.29, pr2 = 0.05, p = 0.21], or age x group x WBV [t (32)< 1,
pr2 = 0.009, p = 0.59].
3.6. Relationship with blood Phe levels
To determine whether there was a relationship between mean blood
Phe levels and brain volume measures in the ETPKU group, additional
analyses were conducted. A series of analyses were performed ex-
amining mean lifetime blood Phe level, mean blood Phe level over the
year prior to scanning, and mean blood Phe level over the previous
three months prior to scanning. For analysis of cerebellar volumes,
hierarchical regression analyses were employed, with age and WBV
entered in the first step, the relevant blood Phe level (i.e., lifetime, past
year, previous 3 months) in the second step, with interaction terms (age
x WBV, age x relevant blood Phe level, WBV x relevant blood Phe level)
in the third step.
3.6.1. Mean lifetime blood phe level
After accounting for age, mean lifetime blood Phe level contributed
significantly to WBV [t (13) = 2.61, pr2 = 0.34, p = 0.02]. Higher
lifetime blood Phe level was associated with lower WBV. However, the
interaction between lifetime Phe level and age did not have a sig-
nificant effect on WBV [t (12)< 1, pr2 = 0.001, p = 0.93].
After accounting for age [t (13) = 2.42, pr2 = 0.31, p = 0.03] and
WBV [t (13) = 7.32, pr2 = 0.81, p < 0.001], there was no significant
effect of lifetime Phe level [t (12) = 1.05, pr2 = 0.08, p = 0.31] on
WCV. Neither the interaction of lifetime Phe level with the age [t (12)
= 1.00, pr2 = 0.10, p= 0.34] or with WBV [t (12) = 1.64, pr2 = 0.23,
p = 0.14] reached significance. Analysis of cerebellar GM and WM
volumes found no significant effects of lifetime Phe level [t (12)< 1,
pr2 < 0.07, p > 0.40 in both cases] or of any interaction effects [t
(11)< 1.5, pr2 < 0.19, p > 0.18 among the interactions].
3.6.2. Mean blood phe level over the previous year, and over the previous
3 months
The effects of mean blood Phe level over the last year and mean
blood Phe level over the previous 3 months mirrored findings for mean
lifetime blood Phe levels. Both measures of blood Phe levels contributed
significantly to WBV after accounting for age [t [16]> 2.2, pr2 > 0.23,
p < 0.05 for both measures], with higher blood Phe levels associated
with lower WBV. No other effects of blood Phe levels or interactions
were significant [p > 0.13 in all cases].
4. Discussion
The present study extends past research on the neurological se-
quelae of ETPKU. Contrary to previous studies [29,33,34], WBV was
not found to be significantly different in individuals with ETPKU as
compared to non-PKU individuals. However, individuals with ETPKU
had significantly reduced cerebellar GM volumes in comparison with
non-ETPKU individuals. No significant group differences were observed
in WCV or cerebellar WM volume.
The most consistent neuroanatomic finding in individuals with
ETPKU is the presence of cerebral WM abnormalities characterized by
hyperintensities on T2-weighted MR imaging and decreased mean dif-
fusivity values using diffusion tensor imaging [35]. These abnormalities
are observed primarily in the posterior periventricular area, extending
anteriorly with increased severity. In terms of volume, Pérez-Dueñas
and colleagues [33] found no differences in overall cerebral WM vo-
lume between individuals with and without ETPKU although, within
K. Aldridge, et al. Molecular Genetics and Metabolism Reports 25 (2020) 100647
4
their ETPKU group, higher blood phe levels were associated with
greater cerebral WM volume. Much less is known regarding the in-
tegrity of WM in the cerebellum, but previous studies suggest that WM
abnormalities in the cerebellum may be less frequent [26–28]. This is
generally in line with the present results showing no ETPKU-related
differences in cerebellar WM volumes. However, we did find a non-
significant trend (p = 0.09) towards an age-by-group interaction, with
cerebellar WM volume decreasing with age in the ETPKU group, while
remaining stable in the non-PKU group. A larger longitudinal study is
needed to fully evaluate the extent to which this trend is trivial or not.
While the cortical WM abnormalities associated with ETPKU are
quite pronounced, the present finding of decreased cerebellar GM vo-
lume in our ETPKU sample adds to a growing literature suggesting that
cortical and subcortical GM structures may also be affected. For ex-
ample, Bodner et al. [34] reported ETPKU-related differences in pu-
tamen volume. Christ et al. [36] documented decreased parietal and
occipital GM volumes in a sample of individuals with ETPKU as com-
pared to individuals without PKU. Most recently, Pilotto et al. [36]
found that higher CSF phe levels were correlated with GM atrophy in
right parietal and bilateral frontal regions in a small sample of in-
dividuals with ETPKU.
The current finding of ETPKU-related effects on cerebellar GM is
also congruent with the findings from past research showing atypical
cell counts and dendritic arborization of Purkinje cells of the cere-
bellum. Additionally, a number of studies of murine models of PKU
have found decreased cerebellar weight, with the cerebellum actually
more affected than the cortex [37,38]. Adelman et al. [39] reported
cytological abnormalities in Purkinje and granular cells of the cere-
bellum. Additional studies have documented abnormalities in cell
number, density, and/or dendritic arborization affecting multiple layers
of the gray matter [38,40,41]. Across this work, the most consistent
finding appears to be that of diminished dendritic arborization, parti-
cularly as it relates to reduced parallel fibers. It is unclear whether si-
milar cellular-level disruptions in humans with ETPKU underlie the
presently observed finding of reduced cerebellar GM volume. Future
studies employing other approaches such as in vivo single-photon
emission computerized tomography (SPECT) to examine receptor den-
sity and/or histological study of post-mortem brain tissue from in-
dividuals with ETPKU may provide insight in this question. [There are a
handful of older histological studies of brain tissue in untreated PKU
[23,24,42]; however, we unaware of any such studies of specimens
from early-treated individuals.] Recent development of a large-animal
model of PKU [43] also holds promise for bridging the gap between
data from murine models and humans.
We found a significant association with WBV and dietary treatment
adherence as reflected by blood Phe levels in the ETPKU group.
However, we failed to find a significant association between any cere-
bellar volume measurement and dietary treatment adherence as re-
flected by blood Phe levels in the ETPKU group. No correlation was
apparent with either lifetime or more recent (past year / past 3 months)
Phe levels. It is possible that future studies employing a larger sample
size (thus increased statistical power) and focusing on Phe levels during
specific developmental epochs which are particularly relevant to cere-
bellum (e.g., birth to 2 years) may reveal relationships between cere-
bellar morphometry and Phe levels that were not evident due to the
limitations of the current study. Additional longitudinal research is
required to understand the complex relationship between Phe levels
and neural development.
Despite the prevalence and severity of the cerebral WM abnormal-
ities frequently observed in individuals with ETPKU, findings on the
relationship between such abnormalities and clinical/functional out-
come are equivocal. Whereas some studies have found a relationship
between WM integrity and neuropsychological function [44–46], others
have failed to do so [47,48]. Although speculative, it is possible that
neurocognitive difficulties in ETPKU may be more closely tied to
markers of GM disruption. Consistent with this, Bodner et al. [33]
reported a significant relationship between putamen volume and
overall intellectual ability in a sample of individuals with ETPKU. Un-
fortunately, neuropsychological data was not available for the present
sample of participants, and the extent to which the current finding of
decreased cerebellar GM may relate to neurocognitive outcome remains
unclear. Moving forward, it will be important to couple neuroimaging
data collection with a comprehensive neuropsychological battery, in-
cluding measures of motor learning and control (i.e., functions that rely
heavily on cerebellum). Additional insight may also be gained by the
application of functional MRI methods to evaluate the efficiency of
neural processing in cerebellum and related brain regions.
4.1. Summary and conclusions
In summary, we found that individuals with ETPKU had reduced
cerebellar GM volumes as compared to healthy non-PKU individuals.
These findings expand on previous animal work suggesting that cere-
bellar GM is impacted by PKU. Additional studies are needed to fully
elucidate the timing and extent of the impact of ETPKU on cerebellum
and the associated neurocognitive consequences.
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